A Phase 3 interventional study of Lebrikizumab and Placebo in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 94 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-11-30.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 4th largest by enrollment, is one of 2 that started in 2019, is one of 17 in phase 3, and was the 4th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 10 more countries
Ages 6 mo–18 yrs
Forefront Dermatology S.C · Sites in United States
Ages 12+
Almirall, S.A.
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 424 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 252 across the 24 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 24 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
30 studies in Dermatitis, Atopic by Eli Lilly and Company: 1 open now, 2 under way, 2 of them phase 3. Of 28 finished, 25 (89%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, this one is the 9th largest by enrollment, is one of 4 that started in 2019, is one of 21 in phase 3, and was the 14th registered.
Eli Lilly and Company’s Dermatitis, Atopic studies by the year they started, since 2013.
3 of the studies testing lebrikizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06526182Phase 3Almirall, S.A.A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-04-25 |
| NCT06906497Johann E Gudjonsson MD PhDLebrikizumab in Moderate-to-severe Atopic Dermatitis | 2027-07 |
| NCT07856134Forefront Dermatology S.CAD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, from their registry updates:
Among Eli Lilly and Company’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment with any of the following agents within 4 weeks prior to the baseline visit:
Treatment with the following prior to the baseline visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction Period (Baseline-Week 16): Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14. Maintenance Period (Week 16-Week 52): Two placebo SC injections as loading dose on Week 16 and Week 18. One placebo SC injection Q2W until Week 50.
Other: Placebo
Induction Period (Baseline-Week 16): 500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14. Maintenance Period (Week 16-Week 52): One 250 mg Lebrikizumab SC injection Q2W until Week 50. For participants who received placebo in the Induction Period, the maintenance loading dose is: Two 250 mg Lebrikizumab SC injections on Week 16. Two 250 mg Lebrikizumab SC injections on Week 18. To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is: One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16. One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18.
Biological: Lebrikizumab · Other: Placebo
Maintenance Period (Week 16-Week 52): One 250 mg Lebrikizumab SC injection every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48. One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50. For participants who received placebo in the Induction Period, the maintenance loading dose is: Two 250 mg Lebrikizumab SC injections on Week 16. Two placebo injections on Week 18. To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is: One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16. Two placebo injections on Week 18
Biological: Lebrikizumab · Other: Placebo
Maintenance Period (Week 16-Week 52): Blinded loading doses based on prior treatment assignment will be administered, followed by one 250 mg Lebrikizumab SC injection Q2W until Week 50 in an open-label fashion. For participants who received placebo in the Induction Period, the loading dose is: Two 250 mg Lebrikizumab SC injections on Week 16. Two 250 mg Lebrikizumab SC injections on Week 18. To maintain the loading dose blind, for participants who received Lebrikizumab in the Induction Period, the loading dose is: One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16. One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18. For participants who do not maintain an acceptable response during the Maintenance Period and entered the Escape Arm, the loading doses will be administrated at entry and 2 weeks after entry based on the treatment assignment prior to entering escape arm.
Biological: Lebrikizumab · Other: Placebo
Subcutaneous injection
Also known as: LY3650150, DRM06
Subcutaneous Injection
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16
The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Time frame: Baseline to Week 16
Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.
Time frame: Baseline to Week 16
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 2
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Time frame: Baseline to Week 2
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 4
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Time frame: Baseline to Week 4
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 in Adults
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Time frame: Baseline to Week 16
Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) From Baseline to Week 16
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the EASI score.
Time frame: Baseline to Week 16
Percent Change in Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." Least Squares (LS) Mean was calculated using analysis of covariance (ANCOVA) model with treatment and randomization strata (region, disease severity, age) as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 16
Percentage of Participants With a Pruritus NRS Score of ≥4-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 16
Percentage of Participants With a Pruritus NRS Score of ≥5-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 16
Percent Change in EASI Score From Baseline to Week 16
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). LS Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate.
Time frame: Baseline, Week 16
Change From Baseline in Percent Body Surface Area (BSA) at Week 16
The BSA affected by AD will be assessed for 4 separate body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. BSA was calculated using the participant's palm using the 1% rule, 1 palm was equivalent to 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 palms for head and neck (10%), 20 palms for upper extremities (20%), 30 palms for trunk, including axilla and groin (30%), 40 palms for lower extremities, including buttocks (40%). Percent of BSA for a body region was calculated as = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of AD.
Time frame: Baseline, Week 16
Percentage of Participants Achieving EASI-90 From Baseline to Week 4
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the EASI score.
Time frame: Baseline to Week 4
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life. LS Mean was calculated using the ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.
Time frame: Baseline, Week 16
Percentage of Participants Achieving ≥4 Point Improvement in DLQI From Baseline to Week 16
The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.
Time frame: Baseline to Week 16
Percentage of Participants With a DLQI Total Score of ≥4-point at Baseline Achieving ≥4-point Improvement in DLQI From Baseline to Week 16
The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.
Time frame: Baseline to Week 16
Percent Change in Sleep-loss Score From Baseline to Week 16
Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Sleep-loss Score at Week 16
Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.
Time frame: Baseline, Week 16
Percentage of Participants With a Sleep-loss Score ≥2 Points at Baseline Who Achieve a ≥2 Points Reduction From Baseline at Week 16
Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary.
Time frame: Baseline to Week 16
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 1
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 2
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 4
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 1
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 2
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 4
Percent Change in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16
The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS Mean was calculated using the ANCOVA model with treatment group and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 16
Pharmacokinetics (PK): Average Serum Concentration of Lebrikizumab at Week 52
PK: Average serum concentration of lebrikizumab at the Week 52 trough timepoint. Serum concentration is a combined measure obtained from Baseline, Week 4, Week 16, Week 32, Week 52 and average measure was reported at week 52.
Time frame: Predose: Baseline, Week 4, Week 16, Week 32, Week 52
Percentage of Participants From Those Re-randomized Having Achieved EASI-75 at Week 16 Who Continued to Exhibit EASI-75 at Week 52 (EASI-75 Calculated Relative to Baseline EASI Score)
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.
Time frame: Baseline to Week 52
Percentage of Participants From Those Re-randomized Having Achieved IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 16 Who Continue to Exhibit and IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 52
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Time frame: Baseline to Week 52
Percentage of Participants From Those With a Pruritus NRS of ≥4-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 52
Percentage of Participants From Those With a Pruritus NRS of ≥5-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Baseline to Week 52
Percent Change in SCORAD (Having Achieved EASI-75 at Week 16) From Baseline at Week 52
The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS mean was calculated using ANCOVA model with treatment group, baseline value, and stratification factors geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 52
Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 16 - Health State Index
The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 16
Change From Baseline in EQ-5D-5L at Week 16 - Visual Analog Scale (VAS)
The EQ-5D-5L is a 2-part measurement. The second part is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 16
Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16
POEM is a 7-item, validated, questionnaire used by the participant to assess disease symptoms over the last week. The participant is asked to respond to 7 questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding and weeping. All 7 answers carry equal weight with a total possible score from 0 to 28 (answers scored as: No days=0; 1# 2 days = 1; 3-4 days = 2; 5#6 days = 3; everyday = 4). A high score is indicative of a poor quality of life. POEM responses will be captured using an electronic diary and transferred into the clinical database. LS Mean was calculated using MMRM model using treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit as covariates, geographic region, age group, baseline IGA (3 versus 4) score as fixed.
Time frame: Baseline, Week 16
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16 - Adolescents
PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 16
Change From Baseline in PROMIS Depression at Week 16 - Adolescents
PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS depression has 8 questions on Emotion Distress-Depression (or Pediatric Depressive Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater depression. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 16
Change From Baseline in PROMIS Anxiety at Week 16 - Adults
PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. The PROMIS measures will be completed by the participant in the study clinic. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 16
Change From Baseline in PROMIS Depression at Week 16 - Adults
PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. The PROMIS measures will be completed by the participant in the study clinic. PROMIS depression has 8 questions on Emotion Distress-Depression (or Pediatric Depressive Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater depression. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 16
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 16 in Participants Who Have Self-Reported Comorbid Asthma
The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. The ACQ-5 score is the average of the individual item scores and ranges from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicate lower asthma control. LS Mean was calculated using ANCOVA with treatment, geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 16
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16 - Adolescents
The CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. The scoring of each question is: Very much =3; Quite a lot = 2; Only a little = 1; Not at all = 0. CDLQI total score is calculated by summing all 10 items responses and has a range of 0 to 30 (higher scores are indicative of greater impairment). LS Mean was calculated using MMRM model which includes treatment, baseline value, visit, the interaction of the baseline value-by-visit as covariates, the interaction of treatment by-visit, geographic region, age group, and baseline IGA (3 versus 4) score as fixed factors.
Time frame: Baseline, Week 16
Participants who did not achieve an Investigator Global Assessment (IGA) of 0 or 1 or EASI-75 at Week 16 and those participants who did not maintain an Eczema Area and Severity Index (EASI)-50 response following re-randomization at Weeks 24, 32, 40, or 48 were assigned to an Escape Arm and received 250 mg Lebrikizumab as open-label Q2W through Week 52.
| Milestone | Induction - Placebo | Induction - Lebrikizumab Q2W | Maintenance Blinded Treatment - Placebo Responder/Placebo (PBO) | Maintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q2W | Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W | Escape Arm Week 16 - Maintenance Open Label - Placebo Nonresponder/ Lebrikizumab 250 Q2W | Escape Arm Week 16 - Maintenance Open Label - Lebrikizumab Nonresponder/ Lebrikizumab 250 Q2W | Escape Arm Week 24 to 48 - Maintenance Open Label Lebrikizumab 250 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 141 | 283 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 141 | 282 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 120 | 263 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 21 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Due to epidemic/pandemic | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 7 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Positive quantiferon test | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 5 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Induction - Placebo | Induction - Lebrikizumab Q2W | Maintenance Blinded Treatment - Placebo Responder/Placebo (PBO) | Maintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q2W | Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W | Escape Arm Week 16 - Maintenance Open Label - Placebo Nonresponder/ Lebrikizumab 250 Q2W | Escape Arm Week 16 - Maintenance Open Label - Lebrikizumab Nonresponder/ Lebrikizumab 250 Q2W | Escape Arm Week 24 to 48 - Maintenance Open Label Lebrikizumab 250 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 4 | 10 | 10 | 32 | 63 | 62 | 0 | 0 | 0 |
| Completed | 0 | 0 | 2 | 10 | 9 | 22 | 54 | 48 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 2 | 0 | 1 | 10 | 9 | 14 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 5 | 0 | 0 | 0 |
| Withdrew: Entered escape arm | 0 | 0 | 1 | 0 | 0 | 7 | 4 | 6 | 0 | 0 | 0 |
| Milestone | Induction - Placebo | Induction - Lebrikizumab Q2W | Maintenance Blinded Treatment - Placebo Responder/Placebo (PBO) | Maintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Placebo Responder/Lebrikizumab 250 Q2W | Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W | Escape Arm Week 16 - Maintenance Open Label - Placebo Nonresponder/ Lebrikizumab 250 Q2W | Escape Arm Week 16 - Maintenance Open Label - Lebrikizumab Nonresponder/ Lebrikizumab 250 Q2W | Escape Arm Week 24 to 48 - Maintenance Open Label Lebrikizumab 250 Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 96 | 106 | 18 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77 | 77 | 15 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 29 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 17 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Easi scoring error | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 | 12.7 (7.0 to 18.5) | 43.1 (37.1 to 49.0) |
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16 | 16.2 (9.5 to 22.8) | 58.8 (52.9 to 64.7) |
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 2 | 0.7 (0.0 to 2.1) | 2.5 (0.7 to 4.4) |
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 4 | 0.8 (-0.7 to 2.3) | 10.6 (6.9 to 14.2) |
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 in Adults | 11.3 (5.4 to 17.2) | 42.2 (35.8 to 48.6) |
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the EASI score.
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) From Baseline to Week 16 | 9.0 (3.9 to 14.0) | 38.3 (32.5 to 44.1) |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." Least Squares (LS) Mean was calculated using analysis of covariance (ANCOVA) model with treatment and randomization strata (region, disease severity, age) as fixed factors and baseline value as covariate.
| percent change | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percent Change in Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16 | -15.06 ± 3.833 | -45.48 ± 3.143 |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With a Pruritus NRS Score of ≥4-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16 | 13.0 (7.0 to 18.9) | 45.9 (39.8 to 52.1) |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With a Pruritus NRS Score of ≥5-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16 | 13.7 (7.5 to 20.0) | 49.0 (42.7 to 55.4) |
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). LS Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate.
| percent change | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percent Change in EASI Score From Baseline to Week 16 | -26.01 ± 4.031 | -64.31 ± 3.156 |
The BSA affected by AD will be assessed for 4 separate body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. BSA was calculated using the participant's palm using the 1% rule, 1 palm was equivalent to 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 palms for head and neck (10%), 20 palms for upper extremities (20%), 30 palms for trunk, including axilla and groin (30%), 40 palms for lower extremities, including buttocks (40%). Percent of BSA for a body region was calculated as = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of AD.
| percentage of body surface area | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in Percent Body Surface Area (BSA) at Week 16 | -11.7 ± 1.86 | -30.2 ± 1.31 |
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the EASI score.
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants Achieving EASI-90 From Baseline to Week 4 | 1.6 (-0.6 to 3.8) | 12.4 (8.5 to 16.3) |
The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life. LS Mean was calculated using the ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.
| score on a scale | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16 | -2.9 ± 1.10 | -8.7 ± 1.05 |
The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants Achieving ≥4 Point Improvement in DLQI From Baseline to Week 16 | 32.4 (23.8 to 41.1) | 71.5 (65.7 to 77.4) |
The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With a DLQI Total Score of ≥4-point at Baseline Achieving ≥4-point Improvement in DLQI From Baseline to Week 16 | 33.8 (24.9 to 42.8) | 75.6 (69.9 to 81.4) |
Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.
| percent change | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percent Change in Sleep-loss Score From Baseline to Week 16 | -15.99 ± 5.139 | -48.33 ± 4.175 |
Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.
| score on a scale | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in Sleep-loss Score at Week 16 | -0.38 ± 0.096 | -1.13 ± 0.078 |
Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary.
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With a Sleep-loss Score ≥2 Points at Baseline Who Achieve a ≥2 Points Reduction From Baseline at Week 16 | 4.7 (0.3 to 9.2) | 39.0 (32.1 to 46.0) |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1 | 0.8 (0.0 to 2.3) | 2.3 (0.5 to 4.1) |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2 | 0.9 (-0.8 to 2.5) | 6.1 (3.2 to 9.0) |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4 | 2.3 (0.0 to 4.9) | 21.5 (16.5 to 26.5) |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1 | 0.8 (0.0 to 2.4) | 2.5 (0.5 to 4.4) |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2 | 0.9 (-0.9 to 2.7) | 6.6 (3.5 to 9.7) |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4 | 2.4 (0.0 to 5.2) | 23.1 (17.8 to 28.5) |
The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS Mean was calculated using the ANCOVA model with treatment group and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
| percent change | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Percent Change in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16 | -16.64 ± 3.162 | -46.93 ± 2.551 |
PK: Average serum concentration of lebrikizumab at the Week 52 trough timepoint. Serum concentration is a combined measure obtained from Baseline, Week 4, Week 16, Week 32, Week 52 and average measure was reported at week 52.
| micrograms per milliliter (ug/mL) | Maintenance 250 mg Lebrikizumab Q4W | Maintenance 250 mg Lebrikizumab Q2W and 250 mg Lebrikizumab Escape Q2W |
|---|---|---|
| Pharmacokinetics (PK): Average Serum Concentration of Lebrikizumab at Week 52 | 40.7 ± 23.7 | 75.7 ± 39.0 |
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.
| percentage of participants | Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W |
|---|---|---|---|
| Percentage of Participants From Those Re-randomized Having Achieved EASI-75 at Week 16 Who Continued to Exhibit EASI-75 at Week 52 (EASI-75 Calculated Relative to Baseline EASI Score) | 61.3 (42.3 to 80.4) | 79.2 (68.0 to 90.4) | 79.2 (67.6 to 90.8) |
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
| percentage of participants | Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W |
|---|---|---|---|
| Percentage of Participants From Those Re-randomized Having Achieved IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 16 Who Continue to Exhibit and IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 52 | 46.5 (24.4 to 68.7) | 74.2 (60.5 to 88.0) | 75.8 (62.9 to 88.7) |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W |
|---|---|---|---|
| Percentage of Participants From Those With a Pruritus NRS of ≥4-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52 | 65.4 (41.5 to 89.3) | 80.4 (63.5 to 97.3) | 81.2 (68.0 to 94.3) |
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W |
|---|---|---|---|
| Percentage of Participants From Those With a Pruritus NRS of ≥5-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52 | 65.4 (41.5 to 89.3) | 83.3 (66.7 to 99.9) | 81.2 (68.0 to 94.3) |
The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS mean was calculated using ANCOVA model with treatment group, baseline value, and stratification factors geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
| percent change | Maintenance Blinded Treatment - Lebrikizumab Responder/Placebo | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q4W | Maintenance Blinded Treatment - Lebrikizumab Responder/Lebrikizumab 250 Q2W |
|---|---|---|---|
| Percent Change in SCORAD (Having Achieved EASI-75 at Week 16) From Baseline at Week 52 | -69.65 ± 3.972 | -71.39 ± 2.870 | -75.28 ± 2.818 |
The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
| score on a scale | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Health State Index UK | 0.0 ± 0.02 | 0.2 ± 0.01 |
| Health State Index US | 0.0 ± 0.01 | 0.1 ± 0.01 |
The EQ-5D-5L is a 2-part measurement. The second part is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
| score on a scale | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in EQ-5D-5L at Week 16 - Visual Analog Scale (VAS) | 2.1 ± 1.64 | 10.4 ± 1.33 |
POEM is a 7-item, validated, questionnaire used by the participant to assess disease symptoms over the last week. The participant is asked to respond to 7 questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding and weeping. All 7 answers carry equal weight with a total possible score from 0 to 28 (answers scored as: No days=0; 1# 2 days = 1; 3-4 days = 2; 5#6 days = 3; everyday = 4). A high score is indicative of a poor quality of life. POEM responses will be captured using an electronic diary and transferred into the clinical database. LS Mean was calculated using MMRM model using treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit as covariates, geographic region, age group, baseline IGA (3 versus 4) score as fixed.
| score on a scale | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16 | -3.9 ± 0.72 | -11.3 ± 0.47 |
PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
| T-score | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16 - Adolescents | -2.80 ± 2.435 | -3.87 ± 1.830 |
PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS depression has 8 questions on Emotion Distress-Depression (or Pediatric Depressive Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater depression. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
| T-score | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in PROMIS Depression at Week 16 - Adolescents | -0.11 ± 2.165 | -4.62 ± 1.623 |
PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. The PROMIS measures will be completed by the participant in the study clinic. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
| T-score | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in PROMIS Anxiety at Week 16 - Adults | -0.60 ± 0.660 | -3.91 ± 0.475 |
PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. The PROMIS measures will be completed by the participant in the study clinic. PROMIS depression has 8 questions on Emotion Distress-Depression (or Pediatric Depressive Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater depression. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
| T-score | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in PROMIS Depression at Week 16 - Adults | -0.37 ± 0.579 | -3.07 ± 0.416 |
The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. The ACQ-5 score is the average of the individual item scores and ranges from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicate lower asthma control. LS Mean was calculated using ANCOVA with treatment, geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.
| score on a scale | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 16 in Participants Who Have Self-Reported Comorbid Asthma | -0.05 ± 0.117 | -0.14 ± 0.095 |
The CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. The scoring of each question is: Very much =3; Quite a lot = 2; Only a little = 1; Not at all = 0. CDLQI total score is calculated by summing all 10 items responses and has a range of 0 to 30 (higher scores are indicative of greater impairment). LS Mean was calculated using MMRM model which includes treatment, baseline value, visit, the interaction of the baseline value-by-visit as covariates, the interaction of treatment by-visit, geographic region, age group, and baseline IGA (3 versus 4) score as fixed factors.
| score on a scale | Placebo | Lebrikizumab Q2W |
|---|---|---|
| Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16 - Adolescents | -1.0 ± 1.29 | -8.0 ± 0.80 |
Collected over Baseline up to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction - Placebo | 0/141 (0%) | 1/141 (0.7%) | 73/141 (51.8%) |
| Induction - Lebrikizumab 250mg Q2W | 0/282 (0%) | 6/282 (2.1%) | 127/282 (45%) |
| Maintenance Blinded - Lebrikizumab Responder/ Placebo | 0/32 (0%) | 0/32 (0%) | 15/32 (46.9%) |
| Maintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q4W | 0/63 (0%) | 2/63 (3.2%) | 32/63 (50.8%) |
| Maintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q2W | 0/62 (0%) | 0/62 (0%) | 25/62 (40.3%) |
| Maintenance Blinded - Placebo Responder/ Placebo | 0/4 (0%) | 1/4 (25%) | 2/4 (50%) |
| Maintenance Blinded - Placebo Responder/Lebrikizumab Q4W | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Maintenance Blinded - Placebo Responder/ Lebrikizumab Q2W | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Escape Arm Week 16 - Maintenance Open Label (OL) -Placebo Non-Responder/Lebrikizumab Q2W | 0/96 (0%) | 1/96 (1%) | 51/96 (53.1%) |
| Escape Arm Week 16 - Maintenance OL- Lebrikizumab Non-Responder/Lebrikizumab Q2W | 0/106 (0%) | 4/106 (3.8%) | 47/106 (44.3%) |
| Escape Arm Week 24 to 48 - Maintenance Lebrikizumab | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| Event | Induction - Placebo | Induction - Lebrikizumab 250mg Q2W | Maintenance Blinded - Lebrikizumab Responder/ Placebo | Maintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q4W | Maintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q2W | Maintenance Blinded - Placebo Responder/ Placebo | Maintenance Blinded - Placebo Responder/Lebrikizumab Q4W | Maintenance Blinded - Placebo Responder/ Lebrikizumab Q2W | Escape Arm Week 16 - Maintenance Open Label (OL) -Placebo Non-Responder/Lebrikizumab Q2W | Escape Arm Week 16 - Maintenance OL- Lebrikizumab Non-Responder/Lebrikizumab Q2W | Escape Arm Week 24 to 48 - Maintenance Lebrikizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/141 | 0/282 | 0/32 | 0/63 | 0/62 | 1/4 | 0/10 | 0/10 | 0/96 | 0/106 | 0/18 |
| DysmenorrhoeaReproductive system and breast disorders | 0/73 | 0/141 | 0/21 | 0/38 | 0/28 | 0/2 | 0/6 | 0/4 | 0/45 | 1/43 | 0/5 |
| CholecystitisHepatobiliary disorders | 0/141 | 0/282 | 0/32 | 1/63 | 0/62 | 0/4 | 0/10 | 0/10 | 0/96 | 0/106 | 0/18 |
| Somatic symptom disorderPsychiatric disorders | 0/141 | 0/282 | 0/32 | 1/63 | 0/62 | 0/4 | 0/10 | 0/10 | 0/96 | 0/106 | 0/18 |
| MicromastiaReproductive system and breast disorders | 0/141 | 0/282 | 0/32 | 0/63 | 0/62 | 0/4 | 0/10 | 0/10 | 1/96 | 0/106 | 0/18 |
| Covid-19Infections and infestations | 0/141 | 0/282 | 0/32 | 0/63 | 0/62 | 0/4 | 0/10 | 0/10 | 0/96 | 1/106 | 0/18 |
| Thermal burnInjury, poisoning and procedural complications | 0/141 | 0/282 | 0/32 | 0/63 | 0/62 | 0/4 | 0/10 | 0/10 | 0/96 | 1/106 | 0/18 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/141 | 0/282 | 0/32 | 0/63 | 0/62 | 0/4 | 0/10 | 0/10 | 0/96 | 1/106 | 0/18 |
| CellulitisInfections and infestations | 1/141 | 0/282 | 0/32 | 0/63 | 0/62 | 0/4 | 0/10 | 0/10 | 0/96 | 0/106 | 0/18 |
| SepsisInfections and infestations | 1/141 | 0/282 | 0/32 | 0/63 | 0/62 | 0/4 | 0/10 | 0/10 | 0/96 | 0/106 | 0/18 |
| Event | Induction - Placebo | Induction - Lebrikizumab 250mg Q2W | Maintenance Blinded - Lebrikizumab Responder/ Placebo | Maintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q4W | Maintenance Blinded - Lebrikizumab Responder/Lebrikizumab Q2W | Maintenance Blinded - Placebo Responder/ Placebo | Maintenance Blinded - Placebo Responder/Lebrikizumab Q4W | Maintenance Blinded - Placebo Responder/ Lebrikizumab Q2W | Escape Arm Week 16 - Maintenance Open Label (OL) -Placebo Non-Responder/Lebrikizumab Q2W | Escape Arm Week 16 - Maintenance OL- Lebrikizumab Non-Responder/Lebrikizumab Q2W | Escape Arm Week 24 to 48 - Maintenance Lebrikizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 30/141 | 16/282 | 4/32 | 4/63 | 2/62 | 2/4 | 0/10 | 0/10 | 6/96 | 4/106 | 1/18 |
| LeukopeniaBlood and lymphatic system disorders | 0/141 | 0/282 | 0/32 | 0/63 | 0/62 | 1/4 | 0/10 | 0/10 | 0/96 | 0/106 | 0/18 |
| LymphadenopathyBlood and lymphatic system disorders | 0/141 | 0/282 | 0/32 | 0/63 | 0/62 | 1/4 | 0/10 | 0/10 | 2/96 | 0/106 | 0/18 |
| SplenomegalyBlood and lymphatic system disorders | 0/141 | 0/282 | 0/32 | 0/63 | 0/62 | 1/4 | 0/10 | 0/10 | 0/96 | 0/106 | 0/18 |
| Covid-19Infections and infestations | 3/141 | 5/282 | 1/32 | 8/63 | 2/62 | 0/4 | 1/10 | 0/10 | 4/96 | 2/106 | 1/18 |
| Abscess limbInfections and infestations | 0/141 | 0/282 | 0/32 | 0/63 | 0/62 | 0/4 | 0/10 | 1/10 | 0/96 | 0/106 | 0/18 |
| Chest wall abscessInfections and infestations | 0/141 | 0/282 | 0/32 | 0/63 | 0/62 | 0/4 | 0/10 | 1/10 | 0/96 | 0/106 | 0/18 |
| NasopharyngitisInfections and infestations | 4/141 | 11/282 | 2/32 | 6/63 | 2/62 | 0/4 | 1/10 | 1/10 | 2/96 | 4/106 | 0/18 |
| Oral herpesInfections and infestations | 5/141 | 9/282 | 0/32 | 2/63 | 1/62 | 0/4 | 1/10 | 0/10 | 3/96 | 1/106 | 0/18 |
| TonsillitisInfections and infestations | 2/141 | 1/282 | 0/32 | 0/63 | 0/62 | 0/4 | 1/10 | 1/10 | 2/96 | 1/106 | 0/18 |
All randomized participants.
| Age, Categorical(Participants) | Induction - Placebo | Induction - Lebrikizumab Q2W | Total |
|---|---|---|---|
| <=18 years | 18 | 37 | 55 |
| Between 18 and 65 years | 113 | 225 | 338 |
| >=65 years | 10 | 21 | 31 |
| Sex: Female, Male(Participants) | Induction - Placebo | Induction - Lebrikizumab Q2W | Total |
|---|---|---|---|
| Female | 73 | 141 | 214 |
| Male | 68 | 142 | 210 |
| Race (NIH/OMB)(Participants) | Induction - Placebo | Induction - Lebrikizumab Q2W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 7 | 7 |
| Asian | 31 | 39 | 70 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Black or African American | 16 | 33 | 49 |
| White | 93 | 196 | 289 |
| More than one race | 1 | 4 | 5 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Region of Enrollment(Participants) | Induction - Placebo | Induction - Lebrikizumab Q2W | Total |
|---|---|---|---|
| Canada | 7 | 16 | 23 |
| South Korea | 13 | 21 | 34 |
| Latvia | 6 | 5 | 11 |
| United States | 62 | 128 | 190 |
| Poland | 25 | 56 | 81 |
| Australia | 13 | 26 | 39 |
| France | 0 | 7 | 7 |
| Lithuania | 7 | 11 | 18 |
| Spain | 4 | 9 | 13 |
| Estonia | 4 | 4 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2019 to primary completion in Jun 2021, 20 months.
Results were first posted in Aug 2022, 1 year 2 months after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 20 months is above that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab